BACKGROUND: Survival for acute lymphoblastic leukemia (ALL) decreases with age. Patients across all age groups from a homogeneous ethnic and socioeconomic background were studied to document age effect. MATERIAL AND METHODS: Patients diagnosed from 2005 to 2015 at a university hospital in Northeast Mexico were divided into 4 age groups: infants (< 1), children (≥ 1 to < 16), adolescents (≥ 16 to ≤ 20), and adults (> 20 years). Correlation between age at diagnosis and relapse-free (RFS) and overall survival (OS) was investigated. RESULTS: A total of 377 patients were included. Five-year RFS and OS for children were 55.6% and 66.9%; for adolescents, 36.0% and 48.3%; for adults, 19.5% and 24.1%, respectively. Differences in RFS and OS between age groups were significant (P < .001, P < .001). In the Cox regression model, all age groups reached statistical significance in univariate analysis of mortality. CONCLUSION: Age plays a decisive role in clinical evolution of ALL and strongly influences outcome. Age older than 20 represents a progressive high-risk factor for death.
BACKGROUND: Survival for acute lymphoblastic leukemia (ALL) decreases with age. Patients across all age groups from a homogeneous ethnic and socioeconomic background were studied to document age effect. MATERIAL AND METHODS:Patients diagnosed from 2005 to 2015 at a university hospital in Northeast Mexico were divided into 4 age groups: infants (< 1), children (≥ 1 to < 16), adolescents (≥ 16 to ≤ 20), and adults (> 20 years). Correlation between age at diagnosis and relapse-free (RFS) and overall survival (OS) was investigated. RESULTS: A total of 377 patients were included. Five-year RFS and OS for children were 55.6% and 66.9%; for adolescents, 36.0% and 48.3%; for adults, 19.5% and 24.1%, respectively. Differences in RFS and OS between age groups were significant (P < .001, P < .001). In the Cox regression model, all age groups reached statistical significance in univariate analysis of mortality. CONCLUSION: Age plays a decisive role in clinical evolution of ALL and strongly influences outcome. Age older than 20 represents a progressive high-risk factor for death.
Authors: Erick Crespo-Solis; Karla Espinosa-Bautista; Martha Alvarado-Ibarra; Etta Rozen-Fuller; Fernando Pérez-Rocha; Chantal Nava-Gómez; Maricela Ortiz-Zepeda; José Luis Álvarez-Vera; Christian Omar Ramos-Peñafiel; Luis Antonio Meillón-García; Sergio Rodríguez-Rodríguez; Alan Pomerantz-Okon; Francisco Javier Turrubiates-Hernández; Roberta Demichelis-Gómez Journal: Cancer Med Date: 2018-05-07 Impact factor: 4.452
Authors: Ashanti Concepción Uscanga-Palomeque; Kenny Misael Calvillo-Rodríguez; Luis Gómez-Morales; Eva Lardé; Thomas Denèfle; Diana Caballero-Hernández; Hélène Merle-Béral; Santos A Susin; Philippe Karoyan; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla Journal: Cancer Sci Date: 2018-12-14 Impact factor: 6.716